The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.

Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.

The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.

The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.

First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.

Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.